You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer

Fig. 2

Impact of Ras-Raf mutationnal status on tumor environment. (a) Boxplot diagrams presenting the number of CD8 positive cells per mm2 according to localization (invasive margin, tumor core and total) in WT patients or with RAS-RAF mutation. (b) Representative pictures of HLA1 IHC staining: HLA1 low in the upper left, HLA1 intermediate in the upper middle and HLA1 in the upper right. Representative pictures of HLA1 quantification using QuPath software; HLA1 1+ (yellow) in the lower left, HLA1 2+ (orange) the lower middle and HLA1 3+ (red) in the lower right. Scale bar indicates 100 μm. (c) Boxplot diagrams presenting association between HLA-score determined by QuPath and the pathologist’s score. (d) Boxplot diagrams presenting the HLA-score according to mutational status (WT: wild type, Mu: mutated, n.s: not significant, *: p < 0.05, **: p < 0.01, ****: p < 0.0001)

Back to article page